Michael Crews, DO
Family Medicine · Bland, VANPI 1215915137
Payments from drug & device makers
Across 140 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$527
- Novo Nordisk$272
- AstraZeneca$204
- Bayer$184
- Sunovion Pharmaceuticals Inc.$158
- Pfizer$102
- plus $640 from 16 others
What the payments were for
- Food & beverage$2,088100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 57 | $527 |
| Novo Nordisk | 13 | $272 |
| AstraZeneca | 12 | $204 |
| Bayer | 9 | $184 |
| Sunovion Pharmaceuticals Inc. | 10 | $158 |
| Pfizer | 6 | $102 |
| Lilly USA, LLC | 2 | $85 |
| Exact Sciences | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 5 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Alkermes, Inc. | 3 | $55 |
| Boehringer Ingelheim | 4 | $49 |
| Amarin Pharma, Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $33 |
| Mylan Specialty L.p. | 1 | $32 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Abbott | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Genentech USA, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$104
How this compares
$2,088 in reported general payments places this provider in the 75th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 87 | $85,141 |
| XifaxanRifaximin | 24 | $83,532 |
| JanuviaSitagliptin Phosphate | 65 | $50,773 |
| Rufinamide | 12 | $40,820 |
| JardianceEmpagliflozin | 30 | $37,692 |
| NuedextaDextromethorphan Hbr/Quinidine | 20 | $33,770 |
| MounjaroTirzepatide | 17 | $31,518 |
| Risperdal ConstaRisperidone Microspheres | 12 | $31,116 |
| Invega SustennaPaliperidone Palmitate | 12 | $27,295 |
| LinzessLinaclotide | 46 | $25,568 |
| TradjentaLinagliptin | 36 | $23,298 |
| TrulicityDulaglutide | 15 | $23,057 |
| FarxigaDapagliflozin Propanediol | 32 | $21,208 |
| TrintellixVortioxetine Hydrobromide | 41 | $20,477 |
| OzempicSemaglutide | 21 | $19,975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $102 | $90,832113 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $20 | $83,53224 claims |
| Boehringer IngelheimJardiance, Tradjenta | $49 | $60,99166 claims |
| Johnson & JohnsonRisperdal Consta, Invega Sustenna | $33 | $58,41124 claims |
| Lilly USA, LLCMounjaro, Trulicity | $85 | $54,57532 claims |
| AbbVieLinzess, Vraylar | $527 | $40,21757 claims |
| AstraZenecaFarxiga | $204 | $21,20832 claims |
| Novo NordiskOzempic | $272 | $19,97521 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $59 | $16,12011 claims |
| BayerKerendia | $184 | $15,93814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Bland
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
- Samir AbdelshaheedChesapeake$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.